ITCI
Intra-Cellular Therapies, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website intracellulartherapies.com
- Employees(FY) 561
- ISIN US46116X1019
Performance
-0.7%
1W
+2.73%
1M
-11.16%
3M
+17.36%
6M
-7.11%
YTD
+5.37%
1Y
Profile
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Investment Analysis Report: ITCI
Overview
In this investment analysis report, we will delve into a comprehensive evaluation of ITCI, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operatin...
Technical Analysis of ITCI 2024-05-10
Overview:
In analyzing the technical indicators for ITCI over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...
Recent News & Updates
- 2024-04-16 21:21
- 2024-04-16 19:36
- 2024-04-16 16:06
- 2024-04-16 16:00
Intra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores Big(Investor's Business Daily)
- 2024-04-16 12:19
- 2024-04-16 12:19
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024(Associated Press Finance)
- 2024-04-16 09:08
Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results(Investor's Business Daily)
- 2024-04-16 07:14
- 2024-04-16 07:00
- 2024-04-16 04:06
- 2024-04-15 19:00
- 2024-03-24 10:31
- 2024-03-19 08:30
- 2024-03-18 20:30
- 2024-03-12 01:16
- 2024-03-06 08:00
- 2024-03-05 19:00
- 2024-03-04 07:28
11 Best Small Cap Pharma Stocks to Invest In(Insidermonkey)
- 2024-02-28 05:01
- 2024-02-27 08:00
- 2024-02-26 19:00
- 2024-02-24 09:37
- 2024-02-23 11:59
- 2024-02-23 08:41
- 2024-02-22 22:59
- 2024-02-22 07:53
- 2024-02-22 07:30
- 2024-02-21 18:59
Intra-Cellular: Q4 Earnings Snapshot(Yahoo Finance)
- 2024-02-21 18:30
- 2024-02-19 10:00